Actively Recruiting
Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)
Led by University of Ulm · Updated on 2026-05-01
20
Participants Needed
1
Research Sites
331 weeks
Total Duration
On this page
Sponsors
U
University of Ulm
Lead Sponsor
D
DiaMed GmbH
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is an observations study evaluating safety and efficacy of immunoadsorption compared to plasma exchange in Guillain-Barré Syndrome.
CONDITIONS
Official Title
Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Guillain-Barr�e9 Syndrome according to the criteria by Doorn et al.
- Age 18 years or above
You will not qualify if you...
- Evidence of systemic infection such as C-reactive protein 20 mg/l or above, or nitrite-positive urinary tract infection
- Use of angiotensin converting enzyme inhibitors within 1 week before first treatment
- Other contraindications to immunoadsorption or plasma exchange
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Neurology, University of Ulm
Ulm, Baden-Wurttemberg, Germany, 89081
Actively Recruiting
Research Team
J
Johannes Dorst, Prof
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here